Pipeline
The introduction of new products, through our discovery programmes as well as through alliances with other companies and with research institutes, is Recordati Rare Diseases’ commitment and a fundamental premise for its growth.
The Recordati group constantly develops new specialty products originated either internally or acquired through development agreements with other pharmaceutical companies and research institutes.
Commitment, scientific rigour, capability and highly specialised staff allow us to develop new treatments and to count on an innovative product pipeline.
New products under development
DISCOVERY
PRECLINICAL DEVELOPMENT
PROOF OF CONCEPT TRIALS
LATE STAGE/ REGISTRATION TRIALS
REGISTRATION
PARTNER
RIGHTS
REC 0545 for Maple Syrup Urine Diseases
AP-HP
Global
REC 0559 for Neurotrophic Keratitis
Mimetech
Global
Candidates for neurodegenerative disorders
Global
Life Cycle Management Programs
DISCOVERY
PRECLINICAL DEVELOPMENT
PROOF OF CONCEPT TRIALS
LATE STAGE/ REGISTRATION TRIALS
REGISTRATION
Acute Hyperammonemia due to Propionic Acidemia or Methylmalonic Acidemia in the U.S.
Hemin in pancreatitis post ERCP
Hemin in cardiac surgery
Hemin in renal transplantation